Overview
RT-3 identifies investigational retatrutide, a triple GIP/GLP-1/glucagon receptor agonist. Its published clinical record now includes phase 3 evidence, which is stronger than an announcement alone1,2.
The catalog preparation is not the investigational formulation used in those trials, and no FDA approval is asserted. Mechanism and trial averages cannot establish product equivalence or a guaranteed patient outcome1,2.
Triple-agonist development
Development combined multiple metabolic hormone signals in one peptide. Structural research provides a molecular explanation for engaging the receptor families, while clinical trials test the integrated result3,5.
The progression from phase 2 to phase 3 matters because larger and longer studies address both efficacy and safety more directly. It does not remove the need for regulatory review or validate a separately compounded formulation1,2.
Mechanism of action
GLP-1 and GIP receptor activity connects to incretin and appetite biology; glucagon-receptor activity adds a distinct metabolic pathway. These inputs interact, so a simple claim that the drug burns fat while bypassing intake and physiology is unwarranted3,5.
Structural work supports multi-receptor activity, but it does not demonstrate a clinically isolated contribution from each receptor. The human result belongs to the whole study intervention, with its exposure and escalation design1,2,5.
- 1Hits three receptors at onceRetatrutide is a single peptide engineered to activate GLP-1, GIP and glucagon receptors; structural studies show how it engages all three5.
- 2Turns down appetiteGLP-1 and GIP signalling reduce appetite and food intake and support glucose-dependent insulin release2,3.
- 3Adds a glucagon leverGlucagon-receptor activation adds a third metabolic signal with a strong effect on the liver, where fat fell by 82.4% in 24 weeks at the top dose4.
- 4Delivers whole-body resultsTogether, the three signals produced dose-dependent weight loss reaching 25.0% at 80 weeks, and HbA1c reductions of up to 2.02% in type 2 diabetes1,3.
- GLP-1 receptor
- GIP receptor
- Glucagon receptor
- Appetite regulation
- Metabolic hormone signalling
Phase 2 & published phase 3
The phase 2 obesity trial randomized 338 adults. At 48 weeks, mean reduction in the highest-dose arm was 24.2% versus 2.1% with placebo; gastrointestinal events and dose-related heart-rate increases were reported2.
The published phase 3 obesity trial randomized 2,339 adults without diabetes and followed treatment for 80 weeks. Mean reduction in the highest-dose arm was 25.0% versus 3.9% with placebo; this is the treatment-regimen estimate, not a larger selected-adherence headline1.
In a separate phase 2 liver-fat substudy, the highest-dose arm showed an 82.4% relative liver-fat reduction at 24 weeks versus a 0.3% increase with placebo. Imaging changes do not alone demonstrate improved long-term liver outcomes4.
25.0% phase 3 weight loss1
At 80 weeks, the highest dose averaged 25.0% weight reduction versus 3.9% with placebo across 2,339 adults.
Liver fat cleared4
Liver fat fell by 82.4% at the top dose, and 86% of participants reached normal levels within 24 weeks.
Consistent phase 2 results2
The phase 2 obesity trial reached 24.2% mean weight loss at 48 weeks, versus 2.1% with placebo.
Glycemic control3
In type 2 diabetes, the top dose lowered HbA1c by 2.02% at 24 weeks, alongside robust weight reduction.
Investigational safety context
The phase 2 program reported dose-related gastrointestinal symptoms and heart-rate increases. A favorable mean weight result does not remove the need to examine tolerability, discontinuation and uncommon-event uncertainty2,3.
The larger phase 3 trial extends exposure data but does not establish safe use of a separately compounded preparation, a nasal route or untested combinations. Pregnancy, endocrine and gastrointestinal history, and interacting metabolic therapies require assessment1,2,3.
- Retatrutide remains investigational in this dossier; the compounded product is not trial-equivalent.
- Gastrointestinal symptoms and dose-related heart-rate increases were reported [2].
- Review other incretin products, glucose-lowering medicines and metabolic risks with your provider.
- Pregnancy, breastfeeding, alternate routes and compounded-formulation safety are not established by these trials.
Supply, storage & administration
Published human trials used subcutaneous investigational preparations1,2,3. This compounded vial requires separate confirmation of active ingredient, concentration, route, final formulation and storage; neither the trial method nor a nasal add-on establishes equivalent exposure.
The catalog specifies vial content, not a verified final formulation or storage specification. A lyophilized preparation requires the pharmacy-specified compatible diluent; a ready-to-use liquid does not. Follow the dispensing label for refrigeration, light protection and the beyond-use date, and use aseptic technique with a new sterile needle and syringe6. Dosing is set by your provider.
Questions
RT-3 or TRZ-2?
RT-3 is a triple agonist with published investigational trials. TRZ-2 is tirzepatide, with approved branded dual-agonist preparations; the compounded products do not inherit brand or trial equivalence.
Does the triple mechanism prove superiority?
No. Separate trial populations, durations and estimands prevent a valid superiority claim from headline averages alone.
Why show both phase 2 and phase 3?
They are different studies with different durations and populations; the newer trial extends, rather than replaces, the earlier evidence.
Is 25.0% an individual prediction?
No. It is the mean in a specific trial arm under the reported analysis approach.
Do liver-fat changes prove liver-disease treatment?
No. A substudy imaging endpoint is not a verified long-term clinical or approved-indication outcome.
References
- 1.Phase 3 RCT
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. (opens in a new tab)
Jastreboff AM, Kaplan LM, Davies MJ, et al.. The New England journal of medicine, 2026. PMID 42814954
The 80-week phase 3 obesity trial randomized 2,339 adults; the highest-dose treatment-regimen mean reduction was 25.0% versus 3.9% with placebo.
- 2.Phase 2 RCT
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. (opens in a new tab)
Jastreboff AM, Kaplan LM, Frías JP, et al.. The New England journal of medicine, 2023. PMID 37366315
The 338-person obesity trial reported 24.2% highest-dose mean reduction at 48 weeks versus 2.1% with placebo, with gastrointestinal and heart-rate effects.
- 3.Phase 2 RCT
Rosenstock J, Frias J, Jastreboff AM, et al.. Lancet (London, England), 2023. PMID 37385280
A separate type 2 diabetes trial measured HbA1c and weight changes with placebo and active-comparator arms.
- 4.Phase 2 RCT
Sanyal AJ, Kaplan LM, Frias JP, et al.. Nature medicine, 2024. PMID 38858523
A liver-fat substudy found an 82.4% relative reduction at 24 weeks in the highest-dose arm versus a 0.3% increase with placebo.
- 5.Cell study
Li W, Zhou Q, Cong Z, et al.. Cell discovery, 2024. PMID 39019866
Structural research explored how retatrutide engages GLP-1, GIP and glucagon receptors.
- 6.Guidance / label
Preventing Unsafe Injection Practices (opens in a new tab)
Centers for Disease Control and Prevention. Regulatory guidance / prescribing information, 2024.
Use aseptic technique and a new sterile needle and syringe; opened multi-dose vials generally have a 28-day discard window unless the manufacturer specifies otherwise, never beyond original expiration.
Research summaries are educational and describe published studies, many in animal or cell models. They are not claims that this product treats any condition. Compounded medications are prepared by a licensed 503A pharmacy for individual patients and are not FDA-approved. Statements on this site have not been evaluated by the FDA. Products are dispensed only after review by a licensed provider. This site does not provide medical advice; talk to your provider before starting any therapy.